Journal
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Volume 200, Issue 6, Pages 595-609Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.ajog.2009.04.005
Keywords
cerebral palsy; infant development; magnesium sulfate; metaanalysis; neurologic handicap; pediatric mortality; prematurity; preterm birth; systematic review
Categories
Funding
- Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Institutes of Health
- Department of Health and Human Services
Ask authors/readers for more resources
We conducted a systematic review and metaanalysis of randomized controlled trials to determine whether magnesium sulfate administered to women at risk of preterm delivery before 34 weeks of gestation may reduce the risk of cerebral palsy in their children. Six trials involving 4796 women and 5357 infants were included. Antenatal magnesium sulfate was associated with a significant reduction in the risk of cerebral palsy (relative risk [RR], 0.69; 95% confidence interval [CI], 0.55-0.88), moderate or severe cerebral palsy (RR, 0.64; 95% CI, 0.44-0.92), and substantial gross motor dysfunction (RR, 0.60; 95% CI, 0.43-0.83). There was no overall difference in the risk of total pediatric mortality (RR, 1.01; 95% CI, 0.89-1.14). Minor side effects were more frequent among women receiving magnesium sulfate. In conclusion, magnesium sulfate administered to women at risk of delivery before 34 weeks of gestation reduces the risk of cerebral palsy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available